Mr. Walsh is the President and CEO of Transcend Medical, which is currently conducting multiple international studies including a U.S. pivotal trial, for a micro-stent ocular implant designed to halt the progression of glaucoma, the leading cause of irreversible blindness in adults.
Mr. Walsh joined Transcend Medical with more than twenty years of medical technology experience, almost exclusively focused on high-growth companies successfully introducing minimally invasive technologies and solutions. His leadership and dedication have helped to provide significant advancements to physicians and patients worldwide, especially in the fields of cardiac surgery and interventional cardiology.
Prior to joining Transcend Medical Mr. Walsh was the Vice President of Sales and Marketing of Xtent, Inc., a publicly-traded company developing next-generation drug- eluting stent systems. In previous leadership roles Mr. Walsh served as Vice President of Sales and Marketing of Ventrica, a developer of automated magnetic devices for cardiac surgery, which was acquired by Medtronic in January 2004, and as Director of Sales for Artemis Medical, Inc., a medical device company which was acquired by Johnson & Johnson.
Mr. Walsh began his medical technology career by progressing through a variety of sales and sales training positions at Guidant, Devices for Vascular Intervention and Marion Merrell Dow. He later served as a sales, marketing and research and development consultant at the Cardiovations Division of Ethicon, and with Heartport, where he held the position of Director of Sales, N.E. US prior to its acquisition by Johnson & Johnson. Mr. Walsh holds a B.S. in Marketing from St. Joseph’s University.